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ABSTRACT
Otitis media with effusion (OME) is the most common cause of
hearing loss in children, and tympanostomy (ear tube insertion) to
alleviate the condition remains the commonest surgical intervention in
children in the developed world. Chronic and recurrent forms of otitis
media (OM) are known to have a very substantial genetic component;
however, until recently, little was known of the underlying genes
involved. The Jeff mouse mutant carries a mutation in the Fbxo11
gene, a member of the F-box family, and develops deafness due to a
chronic proliferative OM. We previously reported that Fbxo11 is
involved in the regulation of transforming growth factor beta (TGF-β)
signalling by regulating the levels of phospho-Smad2 in the epithelial
cells of palatal shelves, eyelids and airways of the lungs. It has been
proposed that FBXO11 regulates the cell’s response to TGF-β
through the ubiquitination of CDT2. Additional substrates for FBXO11
have been identified, including p53. Here, we have studied both the
genetic and biochemical interactions between FBXO11 and p53 in
order to better understand the function of FBXO11 in epithelial
development and its potential role in OM. In mice, we show that
p53 (also known as Tp53) homozygous mutants and double
heterozygous mutants (Jf/+ p53/+) exhibit similar epithelial
developmental defects to Fbxo11 homozygotes. FBXO11 and p53
interact in the embryonic lung, and mutation in Fbxo11 prevents the
interaction with p53. Both p53 and double mutants show raised levels
of pSMAD2, recapitulating that seen in Fbxo11 homozygotes.
Overall, our results support the conclusion that FBXO11 regulates
the TGF-β pathway in the embryonic lung via cross-talk with p53.
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INTRODUCTION
Otitis media with effusion (OME) is the commonest cause of
hearing loss in children, and has effects on language development
and learning, accompanied by behavioural problems. It is the
most common cause of surgery for children in the developing world,
involving the insertion of tympanostomy tubes. Genetic studies in
the human population demonstrate that there is a substantial genetic
component to chronic OME (COME) (Casselbrant et al., 1999,
2009; Rovers et al., 2002; Daly et al., 2004; Hafren et al., 2012b),
but very little is known about the underlying genes and pathways
involved. However, a number of single gene mutations in mouse
give rise to COME phenotypes, in some cases accompanied by a
spectrum of other disorders (Rye et al., 2011a), and provide
important tools for understanding the pathways and mechanisms
underlying chronic middle-ear inflammatory disease.
We have studied three mouse models of COME, Jeff (Jf )
(Hardisty-Hughes et al., 2006), Junbo (Parkinson et al., 2006) and a
knockout of the Tgif1 gene (Tateossian et al., 2013). The Jf and
Junbo mutants carry mutations in the Fbxo11 and Evi1 genes,
respectively, and all three genes (Fbxo11, Evi1 and Tgif1) impact
upon TGF-β signalling. EVI1 is a co-repressor of SMAD3, whereas
TGIF1 functions as a regulator of the TGF-β signalling pathway.
The development of COME in these mutants might reflect the
interplay between TGF-β and hypoxia signalling pathways
(Cheeseman et al., 2011). Hypoxia is a feature of inflamed
microenvironments and there is cross-talk between TGF-β and
hypoxia-inducible factor-1α (HIF-1α) signalling pathways. We
investigated the occurrence of hypoxia and HIF-mediated responses
in Junbo and Jf mutants, and showed cellular hypoxia in the white
blood cells of both the middle-ear mucosa and middle-ear lumen
(Cheeseman et al., 2011).
Our previous studies of the Jf mutant indicate that FBXO11 is
involved in controlling TGF-β signalling by regulating the levels of
pSMAD2 in embryonic epithelial cells (Tateossian et al., 2009).
Whereas Jf heterozygous mice develop deafness due to chronic
proliferative otitis media (OM) (Hardisty et al., 2003; Hardisty-
Hughes et al., 2006), Jf homozygotes display developmental
epithelial abnormalities, including underdeveloped lungs
(Tateossian et al., 2009). The TGF-β signalling pathway is
integral for normal lung development, with all three TGF-β
isoforms being expressed in embryonic lung (Bartram and Speer,
2004). It has been shown that these isoforms can negatively regulate
lung branching morphogenesis in early lung development (Sakurai
and Nigam, 1997; Liu et al., 2000). In contrast, downregulation of
TGFβRII stimulates embryonic lung branching in vitro (Zhao et al.,
1996). SMAD2 and SMAD3 knockouts have markedly different
phenotypes, with knockout of SMAD2 leading to early embryonic
lethality (Weinstein et al., 1998), whereas SMAD3 knockouts
survive to term but show airspace enlargement and abnormal
alveolarization (Chen et al., 2005). In adult lungs, TGF-β signalling
is a key driver of remodelling after injury in diseases such as asthma,
idiopathic fibrosis (IPF) and chronic obstructive pulmonary disease
(COPD). In addition, single nucleotide polymorphisms (SNPs) in
both SMAD3 and TGFβRII have been associated with lung function
changes in a recent genome-wide association study (Postma and
Timens, 2006; Moffatt et al., 2010; Liao et al., 2014; Pain et al.,
2014).
FBXO11 is a member of the F-box family of proteins that are the
substrate-recognition components of the SCF ubiquitin-ligase
complexes containing Skp1, Cullin, Rbx1/Roc1/Hrt1 RING
domain protein and an F-box protein. These proteins are
important regulators of many cellular processes such as DNAReceived 24 July 2015; Accepted 12 October 2015
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replication, mitosis, DNA repair, transcription, cell differentiation
and cell death (Cardozo and Pagano, 2004). FBXO11 has been
identified as an E3 ligase for p53, which can promote the
neddylation and suppress transcriptional activity of p53 (Abida
et al., 2007). FBXO11 has also been shown to target the oncoprotein
BCL6 (B cell lymphoma 6) for degradation (Duan et al., 2012). The
recent identification of FBXO11 as a regulator of TGF-β signalling
by controlling CDT2 activity has revealed a new avenue of TGF-β
regulation (Abbas et al., 2013a,b; Rossi et al., 2013). The CRL4Cdt2
E3 ubiquitin ligase is a known regulator of cell cycle progression
and genome stability. CDT2 was found to be degraded by CUL1-
FBXO11 (CRL1FBXO11), which results in stabilization of p21 and
SET8. It has been proposed that the epithelial defects in Jf mice
might arise from impaired SET8 levels (Abbas et al., 2013b).
Because SET8 seems to promote SMAD2 de-phosphorylation, by
an unknown mechanism, the high levels of pSMAD2 observed in Jf
mutants could reflect a compromised FBXO11-CDT2-SET8
pathway (Abbas et al., 2013a).
In parallel, it is also known that the TGF-β and p53 pathways
cooperate and a number of genes are under the joint control of p53
and SMADs (Atfi and Baron, 2008). For example, p53 physically
interacts with SMAD2 in vivo and both are recruited at distinct cis-
regulatory elements on a common target promoter, leading to
synergistic activation of transcription (Cordenonsi et al., 2003).
Mutant p53 can attenuate the ability of TGF-β1 to induce the
expression of genes encoding p21, PAI-1 (plasminogen activator
inhibitor), MMP2 (matrix metalloproteinase) and SM22 (smooth
muscle specific 22 kDa protein) (Kalo et al., 2007). It has also been
found that Ras signalling induces p53 N-terminal phosphorylation,
enabling the interaction of p53 with activated SMADs and
subsequent recruitment of the complex to specific TGF-β
responsive target promoters (Cordenonsi et al., 2007).
This extensive cross-talk between TGF-β and p53 signalling
pathways suggested a potential role for p53 signalling in epithelial
development. Examining the interactions between TGF-β and p53
signalling pathways in epithelial development will help inform us
about the molecular mechanisms impacting on epithelial function
in the middle ear. We hypothesised that embryonic epithelial
development might be controlled by FBXO11, through its
regulation of the TGF-β pathway, in cooperation with p53. We
therefore studied in detail the genetic and biochemical interactions
of Fbxo11 and p53 (also known as Tp53) in developing mouse
lungs, an organ that has similar properties to the middle ear
(Takahashi, 2001) and for which we have previously demonstrated
that FBXO11 has an important role in modulating TGF-β signalling.
Our results support the conclusion that FBXO11 regulates TGF-β
signalling in murine embryonic lung through interactions with the
p53 pathway.
RESULTS
Developmental abnormalities in p53-deficient mice
It has been reported that a mutation in the p73 gene, a close relative
of p53, results in the development of OM (Yang et al., 2000). We
have tested p53-knockout mice for hearing loss by clickbox and, in
addition, we have analysed histological sections of the bullae of the
mutant mice. We did not detect any difference in the hearing ability
between p53 mutant mice and wild types at the age of 2 months.
Assessing the bulla sections of p53 mutant heterozygote and
homozygote mice revealed no histological changes in the middle ear
of either genotype.
Mice deficient for p53 on a mixed genetic background have been
reported as developmentally normal (Donehower et al., 1992).
However, outcrossing the mice on a 129/sv background results in
embryonic lethality due to defects in neural tube closure (Sah et al.,
1995), and additional developmental abnormalities are reported on a
129/Ola background (Armstrong et al., 1995). Owing to the variable
phenotypes observed on different backgrounds, we first undertook a
detailed investigation of embryogenesis in our p53 mutant colony.
We noted that, in p53 mice maintained on a C57BL/6J background,
a significant proportion of homozygotes died before weaning. The
surviving homozygotes composed 14.3% (25/175) of the mice from
heterozygote intercrosses, less than the expected 25% [χ2=10.71429
P=0.0011, degrees of freedom (d.f.)=1]. Only three out of the 25
adult homozygote mice were female. At embryonic day 18.5
(E18.5), four out of ten homozygote embryos had developmental
abnormalities. All four affected embryos had severely abnormal
TRANSLATIONAL IMPACT
Clinical issue
Otitis media with effusion (OME), the build-up of thick and sticky fluid in
the middle ear in the absence of infection, is the most common cause of
hearing loss in children. Alleviation of the condition by the insertion of a
grommet – a small tube that drains fluid from the middle ear – into the
tympanic membrane (eardrum) remains the commonest surgical
intervention in children in the developed world. However, the
mechanisms by which this procedure, known as a tympanostomy,
leads to improvement of symptoms are not clear. Chronic and recurrent
forms of OM are known to have a very substantial genetic component
and, until recently, little was known of the underlying genes involved. The
identification of mouse models of chronic OM has transformed our
understanding of the genetic pathways involved and is highlighting new
avenues and targets for therapeutic intervention. A number of the mouse
models reported, including the mutants Jeff, Junbo and Tgif1, implicate
the role of the transforming growth factor-beta (TGF-β) signalling
pathway in predisposition to chronic otitis media, and highlight the role
of hypoxia, a feature of an inflammatory microenvironment. The interplay
between the TGF-β signalling pathway and other signalling pathways in
OME requires further investigation.
Results
In this study, the authors examined the interaction between FBXO11, a
member of the F-box family of proteins that is mutated in the Jeff mouse
model, and p53, a putative substrate of FBX011. They previously showed
that FBXO11 controls levels of phosphorylated SMAD2 to regulate
TGF-β signalling during epithelial development. Here, they demonstrate
that, like Fbxo11 (Jeff ) homozygotes, p53 homozygote mutants develop
epithelial developmental abnormalities. They also investigated the
genetic and biochemical interaction of Fbxo11 with p53. Mice
heterozygous for both genes, Jf/+ p53/+, exhibit similar epithelial
developmental defects to Jeff and p53 homozygotes. In mouse
embryonic lungs, FBXO11 co-immunoprecipitates with p53, and p53 is
neddylated (conjugation of the ubiquitin-like protein NEDD8) by FBXO11.
Moreover, raised levels of phosphorylated SMAD2 are detected in p53
homozygote and double heterozygote (Jf/+ p53/+) mutant embryonic
lungs. Taken together, these results support the hypothesis that FBXO11
regulates the TGF-β pathway via cross-talk with p53.
Implications and future directions
This study highlights the role of FBXO11 and its interacting partner, p53,
in epithelial development. The interactions between TGF-β and p53
signalling might be mimicked in OME, potentially providing new insight
into the underlyingmolecular mechanisms of hearing loss. Thus, it will be
important to translate our findings of the interaction of FBXO11 and p53
signalling in lung development to the epithelial cells of the middle ear.
This will further elaborate the pathways and mechanisms underlying
chronic middle-ear inflammatory disease and pave the way for new
treatments to circumvent the need for surgical intervention.
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lung architecture; in addition, one had eyelids open and exencephaly
and two had cleft palate (Fig. 1) – phenotypes that hitherto have
not been reported in p53-deficient mice. Of these four embryos,
three were female and one male. This is consistent with previous
reports that some developmental defects in p53-deficient mice,
such as exencephaly, are known to be female-specific (Sah et al.,
1995).
To analyze the lung phenotype of the embryos, we measured the
width and counted the number of the airways as described
previously (Yates et al., 2013). The E18.5 p53 homozygote lungs
showed significantly reduced airspace width (P=4.33E-06; Fig. 2A,
B) and a significantly reduced number of airspaces compared to
wild-type littermates (P=0.0024; Fig. 2A,C). The remaining six
embryos had less disrupted lung histology and a milder lung
phenotype. These phenotypic features closely resemble those
observed in Jf homozygotes (Hardisty-Hughes et al., 2006;
Tateossian et al., 2009) and likely account for the perinatal
mortality of p53-deficient mice.
Fbxo11 and p53 interact genetically
Given the similarities between Fbxo11 and p53 phenotypes, and our
hypothesis regarding potential interactions between FBXO11 and
p53, we tested for genetic interactions between these two loci. In
our previous study, intercrosses of Jf heterozygotes and p53
homozygotes on a C57BL/6J background produced compound
heterozygotes, most of which survived (Tateossian et al., 2009).
However, in this study, using Jfmice on a mixed C3H/HeH-C57BL/
6J background lead to reduced survival of compound heterozygotes
(19/146, χ2=11.1872 P=0.0008, d.f.=1). The average weight of the
compound mutants was the same as the average weight of Jf
heterozygotes (Fig. S1).
Given that our previous work examining interactions between
FBXO11 and TGF-β signalling had focused on the lungs as one
of the most severely affected organs (Tateossian et al., 2009), we
chose to investigate interactions between FBXO11 and p53 in
the same organ. At E18.5, half of the double heterozygotes (Jf/+
p53/+) examined (5/10) had severely affected lungs and cleft
palate, a phenotype similar to that of Jf homozygote mice
(Tateossian et al., 2009), mice heterozygous for both Jf and
Smad2 (Tateossian et al., 2009), and some p53 homozygote
mice. The average width (P=0.00001; Fig. 2A,B) and number
(P=0.0019; Fig. 2A,C) of airspaces in severely affected double
heterozygotes was significantly lower than in wild types,
recapitulating the lung phenotype of the Jf/Jf embryos and of the
affected p53/p53 embryos, indicating a genetic interaction between
Fbxo11 and p53.
Surviving double heterozygotes looked phenotypically normal
and we therefore intercrossed them. Jf/Jf p53/p53 and Jf/Jf p53/+
embryos were examined at E18.5, E17.5 and E16.5. At E16.5, we
did not find any Jf/Jf p53/p53 homozygotes, indicating that they die
before E16.5, and we found one Jf/Jf p53/+ embryo of normal size
(χ2=2.172414 P=0.140506, d.f.=1), suggesting that Jf/Jf p53/+
mutants die after E17.5 (Table S1).
FBXO11 and p53 are in a complex with CUL1 in the
embryonic mouse lung
In order to assess the biochemical interactions between FBXO11
and p53 in developing epithelia, we focused our analysis on the
lung. Because of to its small size, protein analysis, such as
immunoprecipitation, of middle-ear epithelia is difficult. However,
both the middle ear and the lungs have substantial similarities in
structure and function (Takahashi, 2001).
Fig. 1. Phenotype of p53-knockout mice. (A) View of the palate of an E18.5 p53 homozygote embryo (p53/p53) and a control sibling (p53/+) embryo. The
double-headed arrow indicates the cleft palate. (B) Photograph of a p53/p53 E18.5 embryo with the eyelids open (arrow) phenotype. (C) Sections through
the lungs of an E18.5 p53 homozygote embryo (p53/p53) and a control sibling (p53/+) embryo, showing the homozygous lung phenotype. Note the reduced
number and width of airspaces in the affected p53/p53 homozygote (see also Fig. 2). Scale bars: 200 μm.
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In our previous study, we were not able to demonstrate a
biochemical interaction between p53 and Fbxo11 in lung
(Tateossian et al., 2009). Given the genetic interaction reported
here, we substantially modified our approach to again look for a
biochemical interaction, including the use of alternative antibodies.
Total protein from E15.5 wild-type lungs was immunoprecipitated
with an antibody that detects both the short and long forms of
FBXO11, and we found that p53 does coimmunoprecipitate with
FBXO11 (Fig. 3A, top and second panel). The size of the p53 band
(71 kDa) suggested that the protein is modified. It has been shown
that FBXO11 promotes the neddylation of p53 at Lys320 and
Lys321 (Abida et al., 2007). NEDD8 is 9 kDa and therefore the
expected size of FBXO11-neddylated p53 is 71 kDa. By employing
an anti-NEDD8 antibody, we demonstrated that p53 is neddylated
when complexed with FBXO11 in the E15.5 mouse lung (Fig. 3A,
third panel) and, in addition, the anti-NEDD8 antibody detects a
band with the size of about 71 kDa in the p53 immunoprecipitate
(Fig. 3A, bottom panel). We also undertook reverse
immunoprecipitation using a rabbit anti-p53 antibody. We found
that only the larger isoform of FBXO11 (103 kDa)
coimmunoprecipitates with p53 in the mouse lung (Fig. 3A,
fourth panel). To test whether the Jf mutation prevents the
association of FBXO11 with p53, we conducted an
immunoprecipitation with total protein isolated from E15.5 Jf
homozygote lungs. The anti-FBXO11 antibody precipitated
FBXO11 from the mutant embryonic lungs (Fig. 3B, second
panel) but not p53 (Fig. 3B, first panel).
F-box proteins are one of the core subunits of the SCF complex.
Cullins are the other important unit providing a scaffold for the
complex. We sought to determine the interaction of FBXO11 with
CUL1 and CUL4 in E15.5 lungs. We used two anti-FBXO11
antibodies: antibody 177A, which recognises only the larger
FBXO11 isoform, and 178A, which detects both isoforms
(Fig. 3C). As expected, the 178A antibody recognized a single
103 kDa band in the 177A immunoprecipitation corresponding to
the large FBXO11 isoform (ENSMUSP00000005504), whereas,
in the 178A immunoprecipitation, it recognized two bands, the
large 103 kDa isoform but also the small 95 kDa isoform
(ENSMUSP00000130379) (Fig. 3D, bottom panel). Surprisingly,
we found that CUL4 was coimmunoprecipitated with the 178A anti-
FBXO11 antibody but not 177A, suggesting that the small isoform
of FBXO11 is in a complex with CUL4 (Fig. 3D, second panel). It
has been reported that the short isoform of FBXO11 binds CDT2
and plays the key role in CDT2 degradation in the FBXO11-CDT2-
Fig. 2. Characterization of lung phenotypes in p53/p53 homozygotes and Jf/+ p53/+ double heterozygote mice. (A) Haematoxylin- and eosin-stained
sections through E18.5 embryo lungs showing lung phenotypes from a variety of genotypes. Scale bars: 1 mm and 200 μm. (B) Comparisons of the width of 20
airspaces from three different regions for three embryos of each genotype. (C) Comparisons of the number of airspaces for three 4×105-μm2 regions for three
embryos of each genotype. The sections were taken at random for the three embryos from each genotype. Bars: standard error of mean (s.e.m.). **P<0.01 and
***P<0.001.
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SET8 pathway (Abbas et al., 2013b). CDT2 also binds to CUL4
through the cullin 4-RING ubiquitin ligase. We found that CDT2
was also coimmunoprecipitated with the 178A anti-FBXO11
antibody (Fig. 3D, third panel). It is possible that the short
isoform of FBXO11 is binding to CDT2 in mouse lung tissue as
part of this complex and, as a consequence, CUL4 is
coimmunoprecipitated. An anti-CUL1 antibody detected two
bands in both immunoprecipitations, using 177A and 178A,
indicating that the larger isoform, which interacts with p53, is in
an SCF complex with CUL1 (Fig. 3D, top panel).
Structural analysis demonstrates possible interactions
between FBXO11 and p53
Following the demonstration that the Jf mutation interferes with the
interaction between FBXO11 and p53, we sought to better
understand the structural relationship between the FBXO11-p53
protein-protein interaction. FBXO11 is a 930-amino-acid F-box
protein that contains a proline-rich domain and the F-box domain
at the N-terminus, three central CASH (carbohydrate-binding
proteins and sugar hydrolysis) domains and a zinc-finger domain
at the C-terminus. The Jf mutation, a non-conservative glutamine-
to-leucine change (Hardisty-Hughes et al., 2006), is located at the
beginning of the second CASH domain (Fig. 4A). CASH domains
are found in over 1000 proteins and consist of repeats of
approximately 7 to 11 right-handed β-helixes (Ciccarelli et al.,
2002). Structural analysis demonstrates the possible biochemical
basis for FBXO11 interaction with the transactivation domain of
p53. Utilising protein docking predictions, we found that the second
CASH domain forms a deep hydrophobic cleft into which the
α-helix that is present in the N-terminus transactivation domain of
p53 can bind (Fig. 4B,D). A similar lock-and-key mechanism is
seen with the MDM2 (murine double minute 2)-p53 interaction
(Kussie et al., 1996; Moll and Petrenko, 2003). MDM2 is one of the
regulators of p53 and acts as an E3 ligase to promote p53
ubiquitination and neddylation. MDM2 interacts with the
transactivation domain of p53 (Kussie et al., 1996) and
ubiquitinates and neddylates amino acids at the C-terminus of
p53. FBXO11 is also known to promote the neddylation of amino
acids localized in the C-terminus of p53 (Abida et al., 2007). Our
structural analysis predicted a possible interaction of FBXO11
with the transactivation domain of p53, similar to the one seen with
MDM2. The Jfmutation is centrally located within the hydrophobic
cleft. We therefore hypothesise that the non-polar leucine might
disrupt hydrogen bonds within the binding site (Fig. 4C,E),
weakening FBXO11’s affinity for p53.
FBXO11 neddylates p53 in the developing lung
It has previously been shown that NEDD8 conjugation to the
C-terminus of p53 does not change the subcellular localization of
p53 in H1299 cells (Abida et al., 2007). Immunohistochemical
Fig. 3. Interaction of FBXO11 with p53. (A) Protein
lysate from E15.5 wild-type embryonic lungs was used
for immunoprecipitation using an anti-FBXO11 (top,
second and third panel) or an anti-p53 (fourth and fifth
panel) antibody. Normal rabbit IgG was used as a
control (IgG). Western blots were probed with antibodies
as indicated: p53 (panel 1); FBXO11 (178A which
detects both large and small isoforms of FBXO11, 103
and 95 kDa; panel 2 and 4); NEDD8 (panel 3 and 5).
A degradation band observed with FBXO11 is indicated
by an asterisk. (B) Protein lysate from E15.5 Jeff
homozygote (Hom) lungs was used for
immunoprecipitation using an anti-FBXO11 antibody
(178A). Normal rabbit IgG was used as a control (IgG).
The top panel was probed with an anti-p53 antibody, the
bottom with an anti-FBXO11 antibody (178A). (C)
Alignment of the fragments of FBXO11 protein used to
produce the 177A and 178A antibodies for FBXO11.
The epitope recognized by 177A maps to a region
between residue 1 and 50 of human FBXO11, which is
exclusive to the large isoform of mouse FBXO11
(Fbxo11-001). The epitope recognized by 178A maps
to a region between residue 877 and 927 of human
FBXO11 and is found in both mouse isoforms
(Fbxo11-001 and 004). (D) Protein lysate from E15.5
wild-type (WT) embryonic lungs was used for
immunoprecipitation using two anti-FBXO11 antibodies:
177A, which detects the large isoform of mouse
FBXO11 (Fbxo11-001, 930 aa, 103 kDa), and 178A,
which detects both the large and small isoforms
(Fbxo11-001, 930 aa, 103 kDa and Fbxo11-004, 855
aa, 95 kDa). The blots were probed with anti-CUL1,
-CUL4, -CDT2 and 178A antibodies. A degradation
band of FBXO11 is indicated by an asterisk.
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analysis of p53 in wild-type and Jf/Jf embryonic lungs showed
that p53 is predominantly localised in the nucleus of the epithelial
cells of the airways, suggesting that the mutation in FBXO11
does not alter localization of p53 (Fig. 5A,B). Western blot
analysis with anti-p53 antibody on wild-type and mutant lung
tissue detected three main bands at approximately 53, 60 and
71 kDa (Fig. 5C). It is well known that the p53 protein is post-
translationally modified in several ways. The 53 kDa band probably
corresponds to unmodified p53 or phosphorylated/acetylated p53.
The 60 kDa band could be either monoubiquitinated (ubiquitin is
8.5 kDa) or monosumoylated (SUMO proteins are 12 kDa) p53.
However, an anti-SUMO-1 antibody recognized some sumoylated
proteins but not of the same size (60 kDa) in embryonic lung lysates
(Fig. 5E). This result suggests that the 60 kDa protein could
correspond to the monoubiquitinated p53. Probing the western blot
with an anti-NEDD8 antibody identified at least three proteins sized
between 71 and 90 kDa that are neddylated in lung lysates,
including a 71 kDa band (Fig. 5F). Two proteins are known to
promote p53 neddylation, MDM2 and FBXO11. Three lysine
residues in the C-terminus of p53 are required for neddylation of
p53 by MDM2 (Xirodimas et al., 2004; Xirodimas, 2008) and two
for neddylation by FBXO11 (Abida et al., 2007). Given the size of
NEDD8 (9 kDa), the FBXO11 interaction with a 71 kDa modified
form of p53 detected by us and that the anti-NEDD8 antibody
recognized a 71 kDa band in the p53 pulldown (see above), we
conclude that the 71 kDa band corresponds to neddylated p53. We
observed decreased levels of neddylated p53 in Jf/Jf lungs
compared to wild types (P=0.016) (Fig. 5C,D), supporting the
conclusion that FBXO11 neddylates p53 in wild-type developing
lungs. Although there was a significant reduction in neddylated p53
in Jf/Jf homozygotes, there were no significant changes in other
forms of p53 in the homozygous mutant. Neddylated p53 protein
levels were also significantly reduced in E15.5 Jf/+ p53/+
embryonic lungs compared to wild type. Interestingly this
reduction was only observed in the severely affected double
heterozygotes (where cleft palate was also present) (Fig. S2). Our
data strongly suggests that FBXO11 regulates the activity of p53 in
the embryonic lung.
Levels of pSMAD2 in p53/p53mutant and Jf/+ p53/+ double-
mutant embryonic lungs
We reported that FBXO11 modulates the TGF-β signalling
pathway in the developing mouse by regulating SMAD2 activity
(Tateossian et al., 2009). To determine whether pSMAD2 is also
upregulated in embryonic p53 homozygotes, we performed
immunohistochemistry. Because the intensity was different
between the wild-type and the mutant tissues, we quantified the
staining by counting the epithelial cells with nuclear stain in the
airways. The percentage of pSMAD2-positive epithelial cells was
significantly higher in p53/p53 lungs, 88% (226/256), compared to
wild types, 68% (181/260) (P=0.0012) (Fig. 6A,B). In addition, this
increasewas quantified by western blotting (P=0.0002) (Fig. 6C,D).
We also examined the levels of pSMAD2 in Jf/+ p53/+ double-
mutant E15.5 embryonic lungs. We analyzed embryonic lung
lysates from mildly and severely affected double mutants. We
detected a significant increase in the levels of pSMAD2 in severely
affected double mutants compared to wild types (P=0.0291) and
compared to mildly affected Jf/+ p53/+ embryos (P=0.0223)
(Fig. 6E,F).
Differences in the levels of p21 and PAI-1 in wild-type and Jf-
mutant tissues
To investigate further the relationship between FBXO11 and p53 in
the developing mouse, we wished to assess whether FBXO11
might inhibit the activity of p53 in the developing lung. First, we
examined FBXO11 levels in both Jf and p53 wild-type and mutant
tissues. No significant difference was seen between the wild-
type and Jf/Jf lungs for either of the two FBXO11 isoforms
(Fig. 7A).We also did not detect significant differences in the levels
of either FBXO11 isoform between wild-type and mutant p53
lungs (Fig. S3A).
Next, we investigated levels of a number of proteins that are
regulated by both pSMAD2 and p53. These included p21, PAI-1
and MMP2. We detected significantly elevated levels of p21 in Jf
homozygote lungs compared to wild-type tissue (P=0.0262)
(Fig. 7B). We observed a significant reduction in the protein
Fig. 4. Predicted structure of the FBXO11-p53 complex. (A) Localization of
the Jeff mutation (Q578L) in the predicted protein structure of FBXO11 on
Ensembl. CASH, carbohydrate-binding proteins and sugar hydrolysis; Znf,
zinc finger domain. (B-E) Cartoon representation of p53 (green) docked in the
FBXO11 (grey) hydrophobic cleft to form the FBXO11-p53 complex. The wild-
type (WT) complex is on the left with the wild-type residue (Q) coloured purple
(B,D). The putative mutated complex found in the Jeffmutation is indicated on
the right with the mutated amino acid (L) coloured orange (C,E). The mutated
complex has an extended and distorted binding site, possibly contributing to
the loss of binding to p53. Figure produced using The PyMOL Molecular
Graphics System, Version 1.5.0.4 Schrödinger, LLC.
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levels of the inactive form of PAI-1 (50 kDa) (P=0.0251) and a
significant increase in the level of active PAI-1 (43 kDa)
(P=0.0486) in Jf/Jf lung lysate compared to wild type (Fig. 7C).
We did not detect a difference in the protein levels of either the pro-
form (72 kDa) or the active form (64 kDa) of MMP2 between wild-
type and mutant tissues on western blots (Fig. 7D). In contrast,
protein levels of p21, PAI-1 and MMP-2 were unchanged in p53/
p53 embryonic lungs compared to littermate lungs (Fig. S3B-D).
However, we observed a significant increase in levels of p21 protein
in severely affected Jf/+ p53/+ double mutants compared to wild
type (P=0.0004) and to mildly affected embryos (P=0.0093)
(Fig. 6E,G).
No difference in protein levels of BCL6, CDT2 and SET8 in
wild-type and mutant Jf and p53 tissues
An additional avenue that we wished to investigate was whether
FBXO11 might regulate the ubiquitin-mediated degradation of
BCL6. FBXO11 has been found to be mutated in multiple diffuse
large B-cell lymphoma cell lines and this inactivation correlates
with increased levels and stability of BCL6 (Duan et al., 2012).
However, we did not detect any significant difference in the protein
levels of BCL6 in wild-type or Jf-mutant lysates (Fig. 7E). It seems
that, in the mouse embryonic lung, FBXO11 does not control the
degradation of BCL6. Similarly, there was no difference in the
levels of BCL6 between wild-type and p53-mutant embryonic lungs
Fig. 5. Expression of p53 in embryonic lungs. (A) Sections through E15.5 wild-type (+/+) and Jeff homozygote (Jf/Jf ) embryonic lungs stained with an anti-p53
antibody (brown stain). The nuclei were counterstained with haematoxylin. In both the wild-type and mutant epithelial cells of the airways, p53 is predominantly
nuclear (arrow). Scale bars: 20 μm. (B) Comparisons of the percentage of cells positive for p53 in wild-type and homozygote airways. In total, 238 (+/+) and 211
(Jf/Jf ) epithelial cells were counted from the airways of different regions of three embryos for each genotype. Bars: standard error of mean (s.e.m.). No
significant difference was found. (C) Equal amounts of protein lysates from E15.5 wild-type (+/+), heterozygous (Jf/+) and homozygous (Jf/Jf ) lungs were
subjected to PAGE, transferred and probed with an anti-p53 antibody. The antibody detected three main bands (see Results): the 53 kDa band represents
unmodified or acetylated/phosphorylated p53; the 60 kDa band likely represents monoubiquitinated p53; and the 71 kDa band corresponds to neddylated p53.
(D) Comparisons of p53 levels across genotypes after normalizing with an anti-actin antibody. The results presented in the graph are from three independent
experiments. Bars: s.e.m. *P<0.05. (E) Equal amounts of protein lysates from E15.5 wild-type (+/+), heterozygous (Jf/+) and homozygous (Jf/Jf ) lungs were
subjected to PAGE, transferred and probed with an anti-SUMO-1 antibody. The antibody did not detect bands with the size of 60 kDa. A549 cell lysate was used
as a positive control for the anti-SUMO-1 antibody. (F) Equal amounts of protein lysates from E15.5 wild-type (+/+), heterozygous (Jf/+) and homozygous (Jf/Jf )
lungs were subjected to PAGE, transferred and probed with an anti-NEDD8 antibody. The antibody detected at least three bands, one of which was 71 kDa. WB,
western blot.
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(Fig. S3E). Finally, given the known role of FBXO11 in regulating
TGF-β signalling through the degradation of CDT2 and the
consequent stabilization of the substrates SET8 and p21 (Abbas
et al., 2013b; Rossi et al., 2013), we examined protein levels of
CDT2 and SET8 in Jf and p53 mutants. We found no significant
difference in the steady-state levels of either CDT2 or SET8
between wild-type and Jf- or p53-mutant tissues (Fig. 7F,G and
Fig. S3F,G).
DISCUSSION
In order to better understand the pathobiology of OM, a variety of
genetic studies have been undertaken to identify loci that contribute
to susceptibility to COME. A number of candidate-gene association
studies have been reported (Hafren et al., 2012a). One such study
demonstrated significant association with FBXO11, with
replication of this finding within an independent cohort (Rye
et al., 2011b). A previous study by Segade et al. (2006) also reported
a nominal association at this locus. MacArthur et al. (2014) reported
associations at the SMAD2 and SMAD4 loci, mediators of the
TGF-β signalling pathway, along with associations at the TLR4 and
MUC5B loci. These studies are consistent with our findings on the
underlying genes and pathways involved with OME in the mouse
models Jf, Junbo and Tgif1, each of which carry a mutation in genes
known to be involved in the regulation of the TGF-β signalling
pathway.
In addition to candidate-gene association studies, there have been
two GWAS studies described (Rye et al., 2012; Allen et al., 2013).
Rye et al. (2012) identified significant associations at several loci,
Fig. 6. Expression of pSMAD2 and p21 in embryonic lungs. (A) Sections through E15.5 wild-type (+/+) and homozygous p53 (p53/p53) embryonic lungs
stained with an anti-pSMAD2 antibody (brown stain). The nuclei were counterstained with haematoxylin. In both wild-type and mutant epithelial cells of the
airways, pSMAD2 is predominantly nuclear (arrow). Scale bars: 20 μm. (B) Comparisons of the percentage of cells positive for pSMAD2 in wild-type (+/+) and p53
homozygote (p53/p53) airways. In total, 260 epithelial cells in wild types and 256 epithelial cells in p53 homozygotes were counted from airways from different
regions for three embryos from each genotype. (C) Equal amounts of protein lysates from E15.5 wild-type (+/+), heterozygous (p53/+) and homozygous (p53/
p53) lungs were subjected to PAGE, transferred and probed with an anti-pSMAD2 antibody. The antibody detected one main band at about 55 kDa.
(D) Comparisons of pSMAD2 levels across genotypes after normalizing with an anti-actin antibody. The results presented in the graph are from three independent
experiments. (E) Equal amounts of protein lysates from E15.5 wild-type (+/+ +/+) and mildly and severely affected double-mutant (Jf/+ p53/+) lungs were
subjected to PAGE, transferred and probed with anti-pSMAD2 and -p21 antibodies. (F,G) Comparisons of pSMAD2 (F) and p21 (G) levels across genotypes.
Data represents the analysis of four individual embryos from wild-type (+/+ +/+), and mildly and severely affected double heterozygote (Jf/+ p53/+) lungs (based
on the histological observation, without and with cleft palate, respectively) after normalizing with an anti-actin antibody. Bars: standard error of mean (s.e.m.).
*P<0.05, **P<0.01 and ***P<0.001. WB, western blot.
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including CAPN14, GALNT14, BPIFA3 and BPIFA1, identifying
novel candidate genes for further analysis. Interestingly, a mouse
model of BPIFA1 was recently shown to demonstrate an increased
susceptibility to OM (Bartlett et al., 2015). In a second GWAS study
(Allen et al., 2013), a novel susceptibility locus on chromosome 2
was identified, with the relevant SNP lying in the intergenic region
between CDCA7 and SP3.
Overall, the reported association and GWAS studies underline
the power of mouse models in identifying candidate genes and
pathways, as well as validating the functionality of the human loci
identified (Daly et al., 2004; Casselbrant et al., 2009; Rye et al.,
2011a; MacArthur et al., 2014). In this study, we have focused on
the Fbxo11 gene, which is mutated in the OM model Jf (Hardisty-
Hughes et al., 2006) and was identified as a potential OM
susceptibility locus within two separate association studies (Segade
et al., 2006; Rye et al., 2011b). We have now studied its genetic
and biochemical interactions with p53 in order to elaborate its role
within epithelia and its potential impact on the development of
OM.
Avariety of studies have demonstrated a crucial role for FBXO11
in the regulation of TGF-β signalling. In vivo studies of the Jfmutant
have demonstrated markedly elevated levels of pSMAD2 associated
with a variety of developmental epithelial abnormalities, including
cleft palate, eyes open at birth and lung abnormalities (Tateossian
et al., 2009). Recently, two important studies demonstrated a new
role for FBXO11 in ubiquitin-dependent degradation of CDT2 that
is crucial for TGF-β pathway responses, including cell cycle exit
(Abbas et al., 2013a; Rossi et al., 2013). Moreover, p53 has been
shown to be neddylated by FBXO11 in vitro (Abida et al., 2007)
and, given the cross-talk between TGF-β and p53 signalling
pathways, there is the potential for impacts on TGF-β signalling
outputs via the interaction between p53 and FBXO11 in vivo. We
surmised from our studies on the Jf mutant that aspects of
embryonic epithelial development are controlled by FBXO11
through its regulation of the TGF-β pathway in cooperation with
p53. Given the availability of FBXO11 and p53 mutants, we have
undertaken a genetic approach to studying the pathways and
mechanisms involved, including examining the genetic and
biochemical interactions between these two factors. The middle
ear and the airway epithelia have a number of biological properties
in common (Takahashi, 2001), and therefore we have focused our
studies on the developing lung.
Surprisingly, a detailed study of lung development in p53
mutants identified an epithelial defect in a large proportion of
homozygotes (around 40%). This phenotype had not been reported
before and, although it was not fully penetrant, we observed a
significant number of homozygous mutants with abnormal lung
architecture showing a smaller number of airways of reduced size.
This phenotype was associated with a very significant increase in
the levels of pSMAD2 in the developing lung and a large increase in
the number of epithelial cells positive for pSMAD2. These features
replicate those found in the Jfmutant, although, in the Jfmutant, the
penetrance of the lung phenotype is much higher. In the absence of
p53 in the developing lung, we saw no effects on the protein
expression of downstream genes, such as p21 and PAI-1. Cell line
studies show that mutant p53 attenuates the ability of the TGF-β
signalling pathway to induce the expression of genes such as p21
and PAI-1 (Cordenonsi et al., 2003).
We adopted various enhancements to investigating FBXO11-p53
interactions and found that, in contrast to our previous report, here
we were able to show that FBXO11 interacts with and neddylates
p53 in the developing lung. In Jf mice, mutant FBXO11 fails to
Fig. 7. Protein expression analysis of E15.5 wild-type (+/+), heterozygote
(Jf/+) and homozygote (Jf/Jf ) lungs. Equal amounts of protein lysates were
subjected to PAGE, transferred and probed with antibodies against FBXO11
(A), p21 (B), PAI-1 (C), MMP-2 (D), BCL-6 (E), CDT2 (F) and SET8 (G). RAW
264.7 whole-cell lysate was used as a positive control for all of the antibodies
except for MMP2, where middle ear effusion lysate was used, and for CDT2,
where adult mouse spleen lysate was used. Graphs show comparisons of the
western blots for each antibody after normalizing with an anti-actin antibody.
The results presented in the graphs are from three independent experiments
for all the antibodies except for p21, where four independent experiments were
used to present the data. Bars: standard error of mean (s.e.m.). *P<0.05.
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interact with p53 and there is a significant reduction in neddylated
p53, although there is no evidence for a corresponding increase in
active p53. The Jf mutant, as with the p53 mutant, shows raised
levels of pSMAD2 (Tateossian et al., 2009). Moreover, in the
presence of normal levels of p53, we find that levels of p21 and PAI-
1 are significantly raised.
Given the similar developmental phenotypes shared by the Jf
and p53 mutants, we examined the phenotypes of double
heterozygote Jf/+ p53/+ mutant mice. The double heterozygotes
showed defects in lung architecture, with extraordinary similarities
to both Jf and p53 homozygous mutants, including a reduced
number of and smaller airways. The phenotypic outcome in the
double mutant was not fully penetrant: only half of the double
mutants were severely affected. The phenotypes observed in the
double mutant demonstrate a genetic interaction between the
Fbxo11 and p53 loci. Moreover, as with the Jf homozygote, we see
increased levels of p21 and pSMAD2 in the double heterozygote
compared to wild type. This implies a similar impact upon
downstream pathways that could reflect a number of factors. These
include lowered levels of FBXO11, which might be expected to
lead to increased activation of p53, even with the lower levels of
p53 found in the heterozygous state. However, it is clear that
the effects of the Fbxo11 and p53 mutants are additive, and that the
reduction in FBXO11 levels does not wholly compensate for the
lower levels of p53 in the double heterozygote in terms of
phenotypic outcomes.
Overall, we conclude that loss of function of either FBXO11 or
p53 leads to developmental epithelial abnormalities in the lung that
are associated with raised pSMAD2 levels. In addition, in double
heterozygous mutants we also observe developmental epithelial
abnormalities that are associated with significantly raised pSMAD2
levels. In the Jf mutant, where normal levels of p53 are maintained,
we see significant increases in p21 and PAI-1 associated with the
increases in pSMAD2, but this is not the case in the p53 mutant,
where p53 is absent. However, in the double heterozygote, where
p53 is present, albeit at reduced levels, we also see significantly
raised levels of p21. Taking the data together, we conclude that
FBXO11 regulates the TGF-β pathway in the embryonic lung via
cross-talk with p53 signalling.
Regulation of the TGF-β pathway by FBXO11 in the developing
lung could reflect influences by the recently identified FBXO11-
CDT2-SET8 pathway or via other routes, or a combination of both.
We studied the levels of CDT2 and SET8 in the developing lung in
both wild-type and mutant Fbxo11 and p53 mice. We found no
significant change in the steady-state levels of these proteins in
either mutant. Ubiquitin-dependent regulation of CDT2 by
FBXO11 occurs via an SCF complex incorporating the cullin-1
RING ubiquitin ligase, and we confirmed in FBXO11 pull-downs
that cullin-1 is present in developing lung tissue. It has been shown
that the short isoform of FBXO11 binds cullin-1 and CDT2 and is
crucial for CDT2 degradation (Abbas et al., 2013b). CDT2 is a
substrate receptor for the cullin-4 ubiquitin ligase, promoting cell
cycle progression through the degradation of SET8 and p21.
Surprisingly, we found that an antibody that recognizes both the
short and long isoforms of FBXO11, pulls down cullin-4, whereas
an antibody recognizing the long isoform only does not. Moreover,
this same antibody also pulls down CDT2. This suggests that the
small form of FBXO11 (which does not interact with p53) binds to
CDT2 within the cullin-4 RING ligase complex, as well as binding
cullin-1. Despite the interactions between FBXO11 and CDT2 in
the developing lung, there is no effect on levels of CDT2 or SET8.
Moreover, the increase in levels of p21 seen in the Jf mutant cannot
be explained by this pathway because knockdown of FBXO11
would be expected to lead to substantial reductions in the levels of
p21 as well as SET8.
In conclusion, our results support the hypothesis that FBXO11
regulates the TGF-β pathway in the embryonic lung via cross-talk
with p53, emphasizing the interplay of these two pathways and a
crucial role of p53 in epithelial development, with consequent
implications for the underlying pathological mechanisms of OM.
MATERIALS AND METHODS
Mice
Jf mutant mice were kept on a mixed C3H/HeH-C57BL/6J background
because it was not possible to maintain them on a congenic C57BL/6J
background. p53 mice were maintained on a C57BL/6J background. The
colonies were genotyped as previously described (Donehower et al., 1992;
Hardisty-Hughes et al., 2006). All animal experimentation was approved by
the Animal Welfare and Ethical Review Body at MRC, Harwell.
Histology
Embryo samples were fixed in 10% buffered formaldehyde. Three-
micrometre-thick paraffin sections were obtained and stained with
haematoxylin and eosin for morphological assessment.
Antibodies
The following primary antibodies were used: p53 (9282), pSMAD2 (3101),
NEDD8 (2754), SET8 (C18B7), SUMO-1 (4930), Cell Signaling; p53 (FL-
393 sc-6243), p21 (C-19; sc-397), PAI-1 (H-135; sc-8979), BCL-6 (N-3;
sc-858), CUL1 (H-213 sc-11384) and CUL4 (H-66 sc-10782), Santa Cruz;
FBXO11 (A301-178A and A301-177A), Bethyl Laboratories; MMP2
(RPCA-MMP2), EnCor Biotechnology Inc.; CDT2 (OAAB00993), AVIVA
Systems Biology; pSMAD2 (AB3849), Millipore; actin (A 2066), Sigma.
RAW 264.7 whole-cell lysate (sc-2211), Santa Cruz and A549 cell lysate,
Cell Signaling were used as positive controls for the antibodies.
Immunoprecipitation
The E15.5 embryos were removed from the uterus of the pregnant mice and
transferred into cold PBS containing a cocktail of protease and phosphatase
inhibitors (catalogue numbers 04 693 124 001 and 04 906 837 001; Roche).
The lungs were then dissected out and the protein samples were prepared as
previously described (Tateossian et al., 2009). For 2.5 mg total protein
extract, 12.5 µg of antibody was used for the immunoprecipitation using
Dynabeads protein G kit (10007D, Invitrogen) as described by the
manufacturer. Rabbit IgG (P120-101 Bethyl Laboratories) was used as a
negative control in IP experiments.
Western blot
Tissue lysates were resolved in 4-12% or 12% NuPAGE Bis-Tris gels
and immunoprecipitates in 7% NuPAGE Tris-Acetate gels (Invitrogen).
They were all blotted onto nitrocellulose membrane (Invitrogen) and
immunostained. Immunoprecipitates were assayed using ReliaBLOT kit
(WB120, Bethyl Laboratories). Antibody dilutions for lung lysates were as
follows: FBXO11, 1:2000; p53, 1:500; pSMAD2 (3101, Cell Signaling)
1:500; p21, 1:1000; PAI-1, 1:1000; MMP-2, 1:500; BCL-6, 1:1000; SET8,
1:500; NEDD8, 1:150; and CDT2, 1:250. Antibody dilutions for
immunoprecipitates were: FBXO11, 1:400; p53, 1:25; CUL1, 1:100; and
CUL4, 1:100. ECL detection system (GE Healthcare) was used.
Immunohistochemistry
For immunohistochemical analysis of E15.5 lungs, the Vectastain Elite
ABC kit (Vector Laboratories, PK 6101) was used according to the
manufacturer’s instructions. Sections were incubated with the anti-p53
antibody (1:100) or anti-pSMAD2 antibody (AB3849, Millipore; 1:200)
overnight at 4°C. DAB+ chromogen system (DAKO K3468) was used to
develop the specific signals and slides were counterstained with
haematoxylin. Some sections were incubated with serum instead of
primary antibody as negative controls.
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Data analysis
A chi-squared test was used to compare the difference between the observed
and the expected number of p53-knockout mice and double-mutant mice. In
other experiments, data was analyzed using unpaired two-tailed Student’s
t-tests. A P-value <0.05 was considered significant and P<0.001 highly
significant.
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